GRAIL to Participate in Upcoming Investor Conferences
GRAIL (Nasdaq: GRAL) has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) has announced its participation in two upcoming investor conferences. The company will conduct fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:30 p.m. ET, and at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida on December 4 at 3:50 p.m. ET. Both sessions will be available via webcast on GRAIL's investor relations website, with replays accessible for at least 30 days following the events.
Details
News Market Reaction – GRAL
The recorded move for GRAL in the trading session of this news was +2.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Piper Sandler 36th Annual Healthcare Conference in
New York, NY : fireside chat on Tuesday, Dec. 3 at 1:30 p.m. ET - 7th Annual Evercore ISI HealthCONx Conference in
Coral Gables, Fla. : fireside chat on Wednesday, Dec. 4 at 3:50 p.m. ET
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-participate-in-upcoming-investor-conferences-302310482.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.